ValuEngine upgraded shares of Mesoblast (NASDAQ:MESO) from a buy rating to a strong-buy rating in a research note published on Monday, ValuEngine reports.

Several other analysts also recently weighed in on the stock. Oppenheimer set a $10.00 price target on shares of Mesoblast and gave the company a buy rating in a research note on Tuesday, September 10th. Cantor Fitzgerald set a $23.00 price target on shares of Mesoblast and gave the company a buy rating in a research note on Tuesday, September 10th. Zacks Investment Research downgraded shares of Mesoblast from a buy rating to a hold rating in a research note on Friday, September 6th. Chardan Capital set a $6.00 price target on shares of Mesoblast and gave the company a hold rating in a research note on Friday, August 30th. Finally, Maxim Group reissued a buy rating and set a $16.00 price objective on shares of Mesoblast in a report on Thursday, September 12th. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $11.67.

Shares of NASDAQ MESO opened at $6.86 on Monday. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.41 and a quick ratio of 1.41. The company has a market cap of $698.75 million, a P/E ratio of -7.53 and a beta of 1.77. Mesoblast has a 1 year low of $3.35 and a 1 year high of $8.78. The firm has a 50-day simple moving average of $5.33 and a two-hundred day simple moving average of $5.18.

Mesoblast (NASDAQ:MESO) last announced its quarterly earnings data on Thursday, August 29th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.02. The business had revenue of $1.97 million during the quarter, compared to the consensus estimate of $1.31 million. Mesoblast had a negative net margin of 536.97% and a negative return on equity of 17.66%. As a group, equities research analysts expect that Mesoblast will post -0.72 EPS for the current year.

A hedge fund recently raised its stake in Mesoblast stock. Morgan Stanley grew its position in Mesoblast limited (NASDAQ:MESO) by 284.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 147,702 shares of the company’s stock after purchasing an additional 109,295 shares during the quarter. Morgan Stanley owned about 0.16% of Mesoblast worth $784,000 at the end of the most recent reporting period. 2.76% of the stock is owned by hedge funds and other institutional investors.

About Mesoblast

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.

Featured Article: Operating Income

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Mesoblast (NASDAQ:MESO)

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.